India, July 1 -- image credit- shutterstock

Morepen Laboratories has issued an update on its recently announced Rs 825 crore CDMO mandate. The first commercial dispatch, valued at approximately Rs 50 crore, has already been completed by the company under the programme during Q1FY2026-27. This marks the successful transition of the mandate from validation and qualification stage to commercial execution stage.

Commenting on the development, Sanjay Suri, Managing Director, Morepen Laboratories, said, "This is an important milestone in Morepen's transition toward long-duration global manufacturing partnerships. Our teams have worked closely with the customer through validation, manufacturing readiness and supply-chain planning. Having start...